ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
Summary
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer, measured in patients blood using CA19-9 as biomarker, determines survival chances and can be used as a quick way to assess treatment effectiveness. This opens up significant prospects for transforming pancreatic cancer from a deadly disease into a chronic one.Moreover, no severe, dose-limiting side effects related to the thermal treatment were observed in any of the patients. Only fatigue was noted in the days following the therapy.Based on these results, ElmediX is planning a Phase II study for pancreatic cancer patients. With seven patent families protecting ElmediX technology, the company has established a strong IP position worldwide (EU, USA, China, and Hong Kong). The company also holds trademarks in the same regions.Co-founders Professor Dr. John-Paul Bogers and Engineer Johan Van den Bossche are respectively the CEO and Chairman of the Board.